Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Soham D Puvvada, Patrick J. Stiff, Michael Leblanc, James R. Cook, Stephen Couban, John P. Leonard, Brad Kahl, Deborah Marcellus, Thomas C. Shea, Jane N. Winter, Hongli Li, Lisa M Rimsza, Jonathan W. Friedberg, Sonali M. Smith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

Original languageEnglish (US)
Pages (from-to)686-691
Number of pages6
JournalBritish Journal of Haematology
Volume174
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Lymphoma
Stem Cells
Transplants
Proteins
Immunohistochemistry
Rituximab

Keywords

  • autologous stem cell transplant
  • BCL2
  • double hit lymphoma
  • double protein lymphoma
  • MYC

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant : subset analysis of randomized trial intergroup SWOG S9704. / Puvvada, Soham D; Stiff, Patrick J.; Leblanc, Michael; Cook, James R.; Couban, Stephen; Leonard, John P.; Kahl, Brad; Marcellus, Deborah; Shea, Thomas C.; Winter, Jane N.; Li, Hongli; Rimsza, Lisa M; Friedberg, Jonathan W.; Smith, Sonali M.

In: British Journal of Haematology, Vol. 174, No. 5, 01.09.2016, p. 686-691.

Research output: Contribution to journalArticle

Puvvada, SD, Stiff, PJ, Leblanc, M, Cook, JR, Couban, S, Leonard, JP, Kahl, B, Marcellus, D, Shea, TC, Winter, JN, Li, H, Rimsza, LM, Friedberg, JW & Smith, SM 2016, 'Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704', British Journal of Haematology, vol. 174, no. 5, pp. 686-691. https://doi.org/10.1111/bjh.14100
Puvvada, Soham D ; Stiff, Patrick J. ; Leblanc, Michael ; Cook, James R. ; Couban, Stephen ; Leonard, John P. ; Kahl, Brad ; Marcellus, Deborah ; Shea, Thomas C. ; Winter, Jane N. ; Li, Hongli ; Rimsza, Lisa M ; Friedberg, Jonathan W. ; Smith, Sonali M. / Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant : subset analysis of randomized trial intergroup SWOG S9704. In: British Journal of Haematology. 2016 ; Vol. 174, No. 5. pp. 686-691.
@article{bf7f948de77c4e579a5be4a8d918c52d,
title = "Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704",
abstract = "Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6{\%}) with MYC overexpression; 20 (74{\%}) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.",
keywords = "autologous stem cell transplant, BCL2, double hit lymphoma, double protein lymphoma, MYC",
author = "Puvvada, {Soham D} and Stiff, {Patrick J.} and Michael Leblanc and Cook, {James R.} and Stephen Couban and Leonard, {John P.} and Brad Kahl and Deborah Marcellus and Shea, {Thomas C.} and Winter, {Jane N.} and Hongli Li and Rimsza, {Lisa M} and Friedberg, {Jonathan W.} and Smith, {Sonali M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/bjh.14100",
language = "English (US)",
volume = "174",
pages = "686--691",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant

T2 - subset analysis of randomized trial intergroup SWOG S9704

AU - Puvvada, Soham D

AU - Stiff, Patrick J.

AU - Leblanc, Michael

AU - Cook, James R.

AU - Couban, Stephen

AU - Leonard, John P.

AU - Kahl, Brad

AU - Marcellus, Deborah

AU - Shea, Thomas C.

AU - Winter, Jane N.

AU - Li, Hongli

AU - Rimsza, Lisa M

AU - Friedberg, Jonathan W.

AU - Smith, Sonali M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

AB - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

KW - autologous stem cell transplant

KW - BCL2

KW - double hit lymphoma

KW - double protein lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84987735570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987735570&partnerID=8YFLogxK

U2 - 10.1111/bjh.14100

DO - 10.1111/bjh.14100

M3 - Article

C2 - 27072903

AN - SCOPUS:84987735570

VL - 174

SP - 686

EP - 691

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -